Australia's most trusted
source of pharma news
Thursday, 17 April 2025
Posted 8 April 2025 AM
New Australian research has put a figure on the widespread off-label use of GLP-1RA medicines triggering shortages of the diabetes drug in Australia and around the world.
In 2022, around one in three dollars earned by pharmas in the United States for GLP1-RAs intended to treat diabetes came from patients who were non-diabetic. The estimate has a wide margin of error, but is backed up by years-long shortages of the medicines.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.